Caco-2

WikiDoc Resources for Caco-2
Articles
Most recent articles on Caco-2 Most cited articles on Caco-2 Review articles on Caco-2 Articles on Caco-2 in N Eng J Med, Lancet, BMJ
Media
Powerpoint slides on Caco-2 Images of Caco-2 Photos of Caco-2 Podcasts & MP3s on Caco-2 Videos on Caco-2
Evidence Based Medicine
Cochrane Collaboration on Caco-2 Bandolier on Caco-2 TRIP on Caco-2
Clinical Trials
Ongoing Trials on Caco-2 at Clinical Trials.gov Trial results on Caco-2 Clinical Trials on Caco-2 at Google
Guidelines / Policies / Govt
US National Guidelines Clearinghouse on Caco-2 NICE Guidance on Caco-2 NHS PRODIGY Guidance FDA on Caco-2 CDC on Caco-2
Books
Books on Caco-2
News
Caco-2 in the news Be alerted to news on Caco-2 News trends on Caco-2
Commentary
Blogs on Caco-2
Definitions
Definitions of Caco-2
Patient Resources / Community
Patient resources on Caco-2 Discussion groups on Caco-2 Patient Handouts on Caco-2 Directions to Hospitals Treating Caco-2 Risk calculators and risk factors for Caco-2
Healthcare Provider Resources
Symptoms of Caco-2 Causes & Risk Factors for Caco-2 Diagnostic studies for Caco-2 Treatment of Caco-2
Continuing Medical Education (CME)
CME Programs on Caco-2
International
Caco-2 en Espanol Caco-2 en Francais
Business
Caco-2 in the Marketplace Patents on Caco-2
Experimental / Informatics
List of terms related to Caco-2

Caco-2 refers to a cell monolayer absorption model. Cell-based functional assays, such as the Caco-2 drug transport model for assessing intestinal transport, are extremely valuable for screening lead compounds in drug discovery.

The Caco-2 cell line was developed by the Sloan-Kettering Institute for Cancer Research through research conducted by Dr. Jorgen Fogh.

The Caco-2 cell line is widely used with in vitro assays to predict the absorption rate of candidate drug compounds across the intestinal epithelial cell barrier. The assay requires that drug absorption rates be determined 21 days after Caco-2 cell seeding to allow for monolayer formation and cell differentiation.

The Caco-2 cell line is a continuous line of heterogeneous human epithelial colorectal adenocarcinoma cells, developed by the Sloan-Kettering Institute for Cancer Research through research conducted by Dr. Jorgen Fogh.

Although derived from a colon (large intestine) carcinoma, when cultured under specific conditions the cells become differentiated and polarized such that their phenotype, morphologically and functionally, resembles the enterocytes lining the small intestine. Caco-2 cells express tight junctions, microvilli, and a number of enzymes and transporters that are characteristic of such enterocytes: peptidases, esterases, P-glycoprotein, uptake transporters for amino acids, bile acids carboxylic acids, etc. They are commercially available through the American Type Culture Collection (ATCC; Manassas, VA, USA).

When looking at Caco-2 cell cultures microscopically, it is evident even by visual inspection that the cells are heterogeneous. As a result, over the years the characteristics of the cells used in different laboratories around the world have diverged significantly, which makes it difficult to compare results across labs.

Caco-2 cells are most commonly used not as individual cells, but as a confluent monolayer on a cell culture insert filter (e.g., Transwell®). When cultured in this format, the cells differentiate to form a polarized epithelial cell monolayer that provides a physical and biochemical barrier to the passage of ions and small molecules . The Caco-2 monolayer is widely used across the pharmaceutical industry as an in vitro model of the human small intestinal mucosa to predict the absorption of orally administered drugs. The correlation between the in vitro apparent permeability (P¬app) across Caco-2 monolayers and the in vivo fraction absorbed (fa) is well established.Transwell diagram

This application of Caco-2 cells was pioneered in the late 1980s by Ismael Hidalgo, working in the laboratory of Ron Borchardt at the University of Kansas, and Tom Raub, who was at the Upjohn Company at the time. Following stints at SmithKline Beecham and Rhone-Poulenc Rorer, Hidalgo went on to co-found a company, Absorption Systems, in 1996, where he remains as Chief Scientist.

The considerable impact of the Caco-2 cell monolayer model can be measured in at least two ways. First, considering that poor pharmacokinetic properties accounted for ~40% of drug failures in development in the early 1990s and only ~10% by 2009, an interval in which Caco-2 monolayers were widely used throughout the pharmaceutical industry to predict absorption, it is not unreasonable to attribute some of that shift to this simple yet powerful model. Second, the 1989 Gastroenterology paper that demonstrated the utility of the model for this application has been cited more than 1000 times since its publication.

The versatility of Caco-2 cells is demonstrated by the fact that, even to this day, they are serving as the basis for the creation of innovative new models that are contributing to our understanding of drug efflux transporters such as P-glycoprotein (ABCB1) and BCRP (ABCG2). RNA interference has been used to silence the expression of individual efflux transporters, either transiently or long-term.

See also

• Cell culture
• Drug development
• Pre-clinical development

References

• Artursson P, Palm K, Luthman K., Caco-2 monolayers in experimental and theoretical predictions of drug transport, Adv Drug Deliv Rev. 2001 Mar 1;46(1-3):27-43.
• Shah P, Jogani V, Bagchi T, Misra A., Role of Caco-2 cell monolayers in prediction of intestinal drug absorption, Biotechnol Prog. 2006 Jan-Feb;22(1):186-98.